Correction to “Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3β/ β-catenin in urinary bladder cancer patients”

Key Points

• A correction note clarifies details about phosphoserine 9 glycogen synthase kinase-3β in bladder cancer.
• The article originally published addresses important clinicohistopathological implications.
• This correction serves to ensure accuracy and reliability in the understanding of β-catenin in relation to urinary bladder cancer.
• The implications for urinary bladder cancer patients are significant, highlighting the need for precise information.